1201438-56-3

1201438-56-3 structure

Name: Duvelisib (IPI-145, INK1197)
Chemical Name: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
CAS Number: 1201438-56-3
Molecular Formula: C₂₂H₁₇ClN₆O
Molecular Weight: 416.863
Catalog: Biochemical Inhibitor PI3K/Akt/mTOR inhibitor (PI3K/Akt/mTOR) PI3K inhibitor
Create Date: 2016-09-01 20:57:02
Modify Date: 2026-07-01 18:29:52
Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

Name	8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
Synonyms	DUVELISIB (IPI-145) IPI-145 INK197 IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197;DUVELISIB (IPI-145; INK1197) INK-1197,Phosphoinositide 3-kinase,IPI 145,IPI145,inhibit,Duvelisib,PI3K,INK 1197,Inhibitor INK-1197 8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone IPI-14 Duvelisib a novel and selective PI3K δ/γ inhibitor 8-chloro-2-phenyl-3-[(1s)-1-(7h-purin-6-ylamino)ethyl]isoquinolin-1-one IPI-145, >= IPI-145 (Duvelisib, INK1197) Dosulin Impurity 3 (Dosulin Impurity C) Duvelisib INK 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone Duvelisib (IPI-145, INK1197) 8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone IPI-145 INK197;DUVELISIB (IPI-145) 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl] IPI-145 Duensibu UNII-610V23S0JI Duvelisib, 10 mM in DMSO duvelisib IPI-145, INK197,Duvelisib DUVELISIB (IPI-145, INK1197);IPI 145; IPI145 Duvelisib Impurity IPI 145 (Duvelisib) DUVELISIB, 1201-3, DUVELISIB [USAN], SURECN153543, UNII-610V23S0JI, IPI145, CHEMBL3039502, MOLPORT-028 IPI-145 (INK-1197) IPI-145, INK 1197, Duvelisib IPI 145 //BP Duvelisib INK1197

Description	Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
Related Catalog	Research Areas >> Cancer
Target	p110δ:2.5 nM (IC50) p110γ:27.4 nM (IC50) p110β:85 nM (IC50) p110α:1602 nM (IC50)
In Vitro	PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells[1].
References	[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795. [2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42.

Density	1.5±0.1 g/cm3
Molecular Formula	C₂₂H₁₇ClN₆O
Molecular Weight	416.863
Exact Mass	416.115234
PSA	88.49000
LogP	4.60
Index of Refraction	1.757
Storage condition	-20°C

1350643-73-0

~94%

1201438-56-3

Literature: Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason Patent: US2012/184568 A1, 2012 ; Location in patent: Page/Page column 83-84 ;